MARAVAI LIFESCIENCES HOLDINGS, INC. financial statements
Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data MARAVAI LIFESCIENCES HOLDINGS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
143
284
799
883
289
259
186
Cost of revenue
66.8
79.6
141
169
149
151
152
Gross profit
76.3
204
659
714
140
108
34
Research and development
3.63
9.3
15.2
18.4
17.3
19.2
17.4
Selling, general and administrative
48.4
94.2
100
129
151
162
145
Operating income
24
120
555
574
-31.6
-236
-215
Interest expense
30
30.7
30.3
20.4
45.9
47.7
27
Interest income
0
0
2.34
27.7
27.4
11.4
Other non-operating income
0.12
0.13
0.28
-0.36
-1.34
-2.34
-4.15
Pre-tax income
-5.85
81.7
531
551
618
-261
-235
Income tax
-0.65
2.88
61.5
60.8
756
-1.86
-4.21
Net income to minority interests
-0.73
-10.2
287
270
-19.3
-115
-100
Net income
-4.47
89
182
220
-119
-145
-131
EBITDA
27.8
125
561
582
-18.8
-215
-192
EPS, basic
-0.03
7.43
1.59
1.67
-0.90
-1.05
-0.90
EPS, diluted
-0.03
2.36
1.56
1.67
-0.90
-1.05
-0.90
Shares, basic (weighted)
254
10.4
115
132
132
138
144
Shares, diluted (weighted)
254
28.9
258
255
132
138
144
Balance sheet
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
24.7
236
551
632
575
322
217
Receivables
51
118
139
54.6
38.5
25.5
Inventory
33.3
51.6
43.2
51.4
50.1
40.5
Other current assets
11.1
19.7
25.8
18.9
18.1
13.4
Total current assets
332
740
848
700
429
296
Property, plant and equipment
101
46.3
52.7
163
164
151
Lease right-of-use assets
49.1
63.9
59.7
52.6
39.3
Goodwill
224
153
284
326
160
129
Intangible assets
178
118
217
221
195
152
Other non-current assets
4.16
53.5
116
77.6
59.8
41.9
Total assets
1,271
1,918
2,282
1,487
1,008
771
Accounts payable
8.17
8.15
5.99
12
2.91
Accrued liabilities
38.5
34.6
53.4
60.2
39.6
36.6
Deferred revenue
78.1
10.2
3.09
3.36
2.38
1.99
Short-term debt
6
6
5.44
5.44
5.44
5.44
Total current liabilities
131
93.8
110
87.5
57
44.9
Long-term debt
529
525
522
519
290
286
Lease liabilities
40.9
51.6
47.5
41.4
34
Other non-current liabilities
2.23
41.1
69
59.5
52.5
36.5
Total liabilities
1,116
1,373
1,377
698
431
398
Total debt
535
531
527
524
296
292
Paid-in capital
85.1
128
138
129
182
199
Retained earnings
0.85
185
405
286
141
10.1
Other comprehensive income
-0.04
0
0
0.52
Shareholders' equity
88.5
315
545
417
325
212
Minority interests
66.2
230
360
373
252
160
Total equity
145
155
545
905
790
577
373
Total liabilities and equity
1,271
1,918
2,282
1,487
1,008
771
Cash flow statement
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-5.2
78.8
469
491
-138
-260
-231
Depreciation and amortization
3.81
5.59
6.41
7.57
12.9
20.9
23.6
Stock-based compensation
1.68
24.6
10.5
18.7
34.6
49.4
30.2
Deferred income tax
-1.16
-5.46
46.9
42.3
755
0.01
-0.02
Change in receivables
-1.89
-33.1
-70.4
-22.3
84.4
14.4
12.8
Change in inventory
0.11
-19.1
-21.6
9.46
0.65
0.38
8
Change in payables
2.47
1.18
0.68
-1.58
5.28
0.72
-7.35
Cash from operations
24.1
152
369
536
126
7.47
-57.6
Capital expenditures
-17.1
-25.4
-14.9
-17.1
-65.6
-29.7
-13.1
Acquisitions
0
-239
-69.6
0
-19
Cash from investing
-17.1
6.07
106
-268
-122
-24.3
-31.4
Debt issued
0
609
0
8.46
0
0.95
Debt repaid
-2.5
-412
-6
-13.9
-5.44
-234
-5.44
Share buybacks
0
-33.7
0
0
Cash from financing
-4.17
53.2
-159
-187
-61.1
-236
-16.5
Exchange rate effect
0.03
0.02
-0.09
0
0
0
-0.03
Net change in cash
2.83
211
315
80.9
-57.2
-253
-106
Free cash flow
6.97
127
354
519
60.7
-22.2
-70.7
Interest paid
28.7
28.9
27.2
20.2
44.3
51
25
Income taxes paid
0.8
5.01
22.5
23
-2.99
0.67
-0.56
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $7.60 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
34.9%
Gross profit / revenue.
Operating margin
-56.1%
Operating income / revenue.
EBITDA margin
-45.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-65.4%
Pre-tax income / revenue.
Net margin
-37.1%
Net income / revenue.
FCF margin
-17.2%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-12.1%
Cash from operations / revenue.
Return on equity (ROE)
-37.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-12.8%
Net income / average total assets.
Return on invested capital (ROIC)
-32.8%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
7.3%
Research and development expense / revenue.
SG&A / revenue
61.4%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
14.3%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
5.1%
Capital expenditures / revenue.
D&A / revenue
10.6%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-28.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-40.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-8.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-68.6%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-63.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
-30.2%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y
-871.2%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-34.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-27.0%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
19.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-23.6%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-30.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-9.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
4.7%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
-17.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
37.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.05x
Current assets / current liabilities.
Quick ratio
2.63x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.82x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.72x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
24.4%
Total debt / total assets.
Liabilities / assets
41.1%
Total liabilities / total assets.
Net debt
$77.0M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.52
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$1.41
Revenue / diluted weighted shares.
FCF per share
-$0.24
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.17
Cash from operations / diluted weighted shares.
Book value per share
$1.38
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
9.45x
Market cap / revenue.
P/B
9.64x
Market cap / shareholders' equity. Only when equity is positive.
EV/Sales
9.82x
Enterprise value / revenue.
FCF yield
-1.8%
Free cash flow / market cap.
Earnings yield
-3.9%
Net income / market cap (the inverse of P/E).
What was MARAVAI LIFESCIENCES HOLDINGS, INC.'s revenue in fiscal 2025?
MARAVAI LIFESCIENCES HOLDINGS, INC. reported revenue of $185.7M for fiscal 2025, 28.3% lower than the year before.
Was MARAVAI LIFESCIENCES HOLDINGS, INC. profitable in fiscal 2025?
No. It reported a net loss of $130.8M.
How much free cash flow did MARAVAI LIFESCIENCES HOLDINGS, INC. generate in fiscal 2025?
Cash from operations of $57.6M minus capital expenditures of $13.1M left free cash flow of -$70.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.